Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin

Phase 3

• Conditions: Small Cell Lung Cancer
• Interventions: Drug: apatinib;etoposide and cisplatin; Drug: placebo;etoposide and cisplatin

• Registration Number: NCT02875457
• Lead Sponsor: Third Military Medical University

Brief Summary

Apatinib has been approved as a second-line treatment for advanced gastric cancer. Several phase III clinical studies of non small cell lung cancer, liver cancer, colorectal cancer and other tumors also showed apatinib has less toxic side effects and better patient tolerance. However, the clinical application of apatinib in small cell lung cancer is still lack of evidence-based medicine. Etoposide and cisplatin chemotherapy is the first-line treatment for small-cell lung cancer. The purpose of this multicenter, randomized, prospective study is to investigate the efficacy and safety of apatinib as the maintenance therapy for extensive stage small cell lung cancer after combined with etoposide and cisplatin chemotherapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-06-11
• Status Verified: 2016-08
• Study First Submitted QC: 2016-08-17
• Study First Posted: 2016-08-23
• Last Update Submitted: 2016-08-23
• Last Update Posted: 2016-08-24
• Study Start: 2016-09
• Primary Completion: 2018-09
• Study Completion: 2023-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Histologic or cytologic diagnosis of small cell lung caner(SCLC), Extensive Stage.
• No prior cisplatin-based chemotherapy or radiotherapy.
• Males or females between 18 Years to 75 Years.
• Performance status of 0～2 on the ECOG criteria.
• Expected survival is above three months.
• At least one measurable lung tumor lesion (according to RECIST criteria, the application of conventional technology, diameter length of the lesion >= 20mm or spiral CT >=10mm).
• Adequate hematologic (Leukocyte count >= 4.0×109/L, neutrophil count>=2.0×109/L, hemoglobin>=95g/L, platelets>=100×109/L), hepatic function (aspartate transaminase (AST) & alanine transaminase(ALT) =<upper normal limit(UNL) x1.5, bilirubin level =< UNL x 1.5).
• Patient can take oral medicine.
• Patients have the ability to understand and voluntarily sign the informed consent, and allow adequate follow-up.

Exclusion Criteria

• History of cardiovascular disease: congestive heart failure (CHF) > New York Heart Association (NYHA) II, active coronary artery disease(patients with myocardial infarction six months ago can be recruited), arrhythmias need to be treated (allow taking beta blockers or digoxin).
• Serious clinical infection (> NCI-CTCAE version 4.0 ,infection standard II).
• Patients with epilepsy who need to take medicine (such as steroids or anti epilepsy agents).
• with brain metastases.
• The patients had accepted allogeneic organ transplantation.
• Bleeding tendency or coagulation disorders.
• patients who need renal dialysis.
• suffered from other tumor within 5 years( Except: cervical carcinoma in situ, cured basal cell carcinoma, cured bladder epithelial tumor).
• uncontrolled hypertension (systolic pressure>150 mmHg , or diastolic pressure> 90 mmHg).
• thrombosis or embolism(cerebrovascular accidents including transient ischemic attack within the last 6 months).
• pulmonary hemorrhage >CTCAE grade 2 within 4 weeks before first use of drugs.
• Other organ hemorrhage >CTCAE grade 3 within 4 weeks before first use of drugs.
• severe uncured wounds, ulcers or fracture.
• uncured dehydration.
• Drugs abuse and medical, psychological or social conditions may interfere with the patient's participation in research or the results of the evaluation effect.
• Patients are allergic to drugs used in research.
• Factors influencing the safety and compliance of patients.
• Inability to comply with protocol or study procedures.
• Pregnant or breast-feeding.
• The researcher believe that the Patient is not suitable to participate in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm A	apatinib;etoposide and cisplatin	Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and apatinib 250mg/d , repeated every 21 days, a total of 6 cycles, and then continue to take apatinib 250mg/d until progressive Disease(PD).
Arm B	placebo;etoposide and cisplatin	Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and placebo, repeated every 21 days, a total of 6 cycles, and then continue to take placebo until PD.

Primary Outcome Measures

Name	Time	Method
Progression-free survival	6 months	The first day of treatment to the date that disease progression is reported.

Secondary Outcome Measures

Name	Time	Method
Tumor response rate	3 months	The ratio between the number of responders and number of patients assessable for tumor response.
Performance Status	the first date of treatment to 30 days after the last dose of study drug, assessed up to 6 months	Performance Status of patients will be assessed by Zubrod-Eastern cooperative oncology group(ECOG)-world health organization(WHO).
Overall survival	5 years	The first day of treatment to death or last survival confirm date.
Treatment-related adverse events	the first date of treatment to 30 days after the last dose of study drug,assessed up to 6 months	Treatment-related adverse events are assessed by common terminology criteria for adverse events(CTCAE) V4.0.